Irkutsk, Irkutsk region, Russian Federation
Irkutsk, Irkutsk region, Russian Federation
V obzore literatury privedeny sovremennye predstavleniya ob antiagregantnoy terapii kak o vazhnom zvene vtorichnoy profilaktiki ishemicheskogo insul'ta. Na osnove dannyh dokazatel'noy mediciny predstavlena harakteristika antiagregantov, voshedshih v klinicheskie rekomendacii i standarty lecheniya bol'nyh ishemicheskim insul'tom. Privedeny osnovnye principy vybora i taktika naznacheniya antitrombocitarnyh sredstv bol'nym ishemicheskim insul'tom na raznyh etapah zabolevaniya.
antiagreganty, antitrombocitarnaya terapiya, vtorichnaya profilaktika, ishemicheskiy insul't
1. Atherothrombotic therapy in patients with stable atherothrombosis manifestations: Russian recommendations. (2009). [Aterotromboticheskaya terapiya u bol’nykh so stabil’nym proyavleniem aterotromboza: Rossiyskie rekomendatsii]. Kardiovaskulyarnaya terapiya i profilaktika, 8 (6), 6-20.
2. Gusev EI, Konovalov AN, Skvortsova VI. (2009). Neurology and neurosurgery: manual [Nevrologiya i neyrokhirurgiya: uchebnik]. Moskva, 420 p.
3. Kurcheva NP, Mirzaev CB, Sychev DA. (2015). Multivariate algorithm of prediction of Clopidogrel antiplatelet action as a potential way to improve the effectiveness and safety of antiplatelet therapy [Mnogofaktornyy algoritm prognozirovaniya antiagregantnogo deystviya klopidogrela, kak potentsial’nyy sposob povysheniya effektivnosti i bezopasnosti antiagregantnoy terapii]. Farmakogenetika i farmakogenomika, (2), 29-32.
4. Interdisciplinary Expert Council of the Russian Society of Angiology and Vascular Surgery, Russian Scientific Society of X-Ray Endovascular Diagnosis and Treatment, National Anti-Stroke Association, National Scientific Society of Inflammation. (2014). The role of testing platelet functional activity in the prevention of cardiovascular complications in patients under antiplatelet therapy [Rol’ testirovaniya funktsional’noy aktivnosti trombotsitov v profilaktike serdechno-sosudistykh oslozhneniy u bol’nykh, poluchayushchikh antitrombotsitarnuyu terapiyu]. Ratsional’naya farmakoterapiya v kardiologii, 10 (6), 679-687.
5. Mirzaev KB, Andreev DA, Sychev DA. (2015). Evaluation of platelet aggregation in clinical practice [Otsenka agregatsii trombotsitov v klinicheskoy praktike]. Ratsional’naya farmakoterapiya v kardiologii, 11 (1), 85-91.
6. Skvortsova VI. (2007). Reduced morbidity, mortality and disability from stroke in the Russian Federation [Snizhenie zabolevaemosti, smertnosti i invalidnosti ot insul’tov v Rossiyskoy Federatsii]. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. Insul’t: prilozhenie k zhurnalu, 25-27.
7. Stakhovskaya LV, Kotov SV. (2014). Stroke: Guidelines for physicians [Insul’t: Rukovodstvo dlya vrachey]. Moskva, 400 p.
8. Sumarokov AB, Shirokov EA, Buryachkovskaya LI. (2015). Antiplatelet therapy in the prevention of ischemic non-cardioembolic stroke. Summary of modern recommendations [Antitrombotsitarnaya terapiya v profilaktike ishemicheskogo nekardioembolicheskogo insul’ta. Osnovnye polozheniya sovremennykh rekomendatsiy]. Moskva, 40 p.
9. Suslin ZA, Varakin YY, Vereshchagin NV. (2009). Clinical and epidemiological studies - a promising direction of studying cerebral pathology (first report) [Kliniko-epidemiologicheskie issledovaniya - perspektivnoe napravlenie izucheniya tserebral’noy patologii (soobshchenie pervoe)]. Annaly nevrologii, (3), 4-11.
10. Suslina ZA, Gulevskaya TS, Maksimova MY, Morgunov VA. (2016). Cerebral circulation disorders: diagnostics, treatment, prevention [Narusheniya mozgovogo krovoobrashcheniya: diagnostika, lechenie, profilaktika]. Moskva, 536 p.
11. Suslina ZA, Fonyakin AV, Geraskina LA, Mashin VVl, Trunov ES, Mashin VV, Glebov MV. (2010). Practical cardioneurology [Prakticheskaya kardionevrologiya]. Moskva, 304 p.
12. Treschinskaya MA. (2015). Choosing antiplatelet agent for secondary prevention of cerebral stroke [Vybor antiagregantnogo sredstva dlya vtorichnoy profilaktiki tserebral’nogo insul’ta]. Mezhdunarodnyy nevrologicheskiy zhurnal, 6 (76), 81-88.
13. Khamidova ZM, Masyutkina LN, Abramycheva NY. (2012). Optimization of the approaches to the prevention of ischemic strokes using pharmacogenetics [Optimizatsiya podkhodov k profilaktike ishemicheskikh insul’tov s ispol’zovaniem vozmozhnostey farmakogenetiki]. Nervnye bolezni, (2), 21-26.
14. Alvarez-Sabin J, Quitana M, Santamarina E, Maisterra O. (2014). Triflusal and aspirin in secondary prevention of atherothrombotic ischemic stroke: a very long-term-follow-up. Cerebrovasc. Dis., 37, 155-234.
15. American Stroke Association. (2011). Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: A guideline for healthcare professionals from the American heart association. Stroke, 42, 227-276.
16. Antithrombotic Trialists’ Collaboration. (2002). Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ, 324, 71-86.
17. Dockerson L, Carek P, Quattlebaum R. (2007). Prevention of recurrent ischemic stroke. American Family Physician, 76 (3), 382-388.
18. European Stroke Organization (ESO) Executive Committee, ESO Writing Committee. (2008). Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc. Dis., 25, 457-507.
19. Hankey G. (2007). Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines. Curr. Med. Res. Opin., 23 (6), 1453-1462.
20. McQuaid KR, Laine L. (2006). Systemic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am. J. Med., 119, 624-638.
21. Storey RF. (2008). New developments in antiplatelet therapy. Eur. Heart J. Supplements, 10, 30-37.
